PubMed Health⌕ Search

Biomedical subjects

M L Friis

Publications and source records attributed to M L Friis.

49 records · Page 3Linked to original sources
PubMed1980

Paramyotonia congenita (von Eulenburg) in Denmark.

Paramyotonia congenita (von Eulenburg) (PMC) is described in a Danish family in seven generations and 39 persons. PMC has not previously been described in Denmark and an epidemiological description of the family is given. The diagnostic difficulties versus hyperkalemic familial periodic paralysis with myotonia, adynamia episodica hereditaria and myotonia congenita (Thomsen) are discussed.

Adolescent↗
PubMed1980

Bromocriptine and Parkinson's disease: a 16-hour clinical evaluation.

The disability score (Webster rating scale) in 12 parkinsonian patients on bromocriptine treatment was evaluated hourly from 06-22 h. Bromocriptine was taken at fixed hours (06, 14, and 22 h) in equal doses. No systematic changes during the day related to bromocriptine ingestion were observed. Only one patient experienced pronounced hyperkinesia, "On-off" phenomenas were not observed during the treatment with bromocriptine.

Aged↗
PubMed1979

Pharmacokinetics of bromocriptine during continuous oral treatment of Parkinson's disease.

The plasma kinetics of bromocriptine (BCT), a long-acting dopamine agonist, was studied in twelve patients with Parkinson's disease, using a newly developed gas chromatographic method of analysis. Each patient received BCT for at least three weeks in a constant but different dose regimen. Concomitant treatment with 1-DOPA was not allowed. During a 6-day hospitalization period, a blood sample was taken immediately before the afternoon dose at 14.00 h (Cmin) to determine the steady-state level. On the 6th day blood samples were collected every hour during two 8 h dose intervals. The results showed a significant correlation between the mean values of the AUC and the Cmin. First order elimination kinetics appeared to be followed by BCT, at least for the plasma concentrations commonly found. Considerable inter-individual variation was demonstrated both for the dose/plasma concentration ratio and for calculated plasma clearances. No serious side-effects were observed during the investigation.

Aged↗
PubMed1979

Transfer of bromocriptine across the blood-brain barrier in man.

The transfer of 14C-bromocriptine across the blood-brain barrier was studied in 10 patients using the double indicator single injection method. The extraction (E) of bromocriptine was 8 % (quartiles: 6 and 14 %). Based on the results the cerebral uptake velocity of bromocriptine was calculated assuming constant arterial drug concentration. Its T 1/2 was found to be 12--24 minutes, depending on the tissue-blood partition coefficient.

Adult↗
PubMed1978

Brain concentrations of carbamazepine and carbamazepine-10,11-epoxide in epileptic patients.

Carbamazepine (CBZ) and carbamazepine-10,11-epoxide (CBZ-Epoxide) in the temporal lobe were measured in five epileptic patients undergoing unilateral temporal lobectomy. The patients had been under CBZ treatment from 6 months to 6 years and all were in steady state at the time of operation. The brain tissue concentration of CBZ in all patients was higher than the plasma concentration; the brain/plasma ratio ranged from 1.4--1.6. Brain/plasma ratios of CBZ-Epoxide ranged from 0.6--1.5. The ratio for CBZ was similar in patients treated with CBZ alone or in combination with other anticonvulsants, but for the CBZ-Epoxide a higher ratio was found in patients on combined treatment. The results may mean that other antiepileptic drugs, too, can influence the brain concentration of an active metabolite, which could have a bearing on the enhanced therapeutic effect often seen on combining CBZ treatment with other antiepileptic drugs.

Adolescent↗
PubMed1978

Carbamazepine, carbamazepine-10,11-epoxide and phenytoin concentrations in brain tissue of epileptic children.

Carbamazepine (CBZ), carbamazepine-10,11-epoxide (CBZ-epoxide) and phenytoin (DPH) were measured in brain tissue in two epileptic children undergoing temporal lobectomy. The patients had been treated with the anticonvulsants in question for 2 years. The CBZ concentration in brain tissue was higher or equal to the plasma concentration. Brain/plasma ratio for CBZ was 1.0 and 1.4, respectively (grey substance). Brain/plasma ratio of CBZ-epoxide was 1.0. Concomitant treatment with DPH increased the percentage of CBZ-epoxide relative to CBZ in both brain and plasma. In white brain substance the concentration of CBZ, CBZ-epoxide and DPH was higher or equal to the corresponding concentration in grey substance. No major age-related differences in the distribution of anti-epileptic drugs between brain and plasma in these two children compared to adult epileptic patients were noted. A new quantitative thin-layer chromatographic method for the determination of DPH and phenobarbital (PB) in brain tissue and plasma is described.

Brain↗